CN Mobile Logo


ASCO 2014 Prostate Cancer

ASCO 2014 Prostate Cancer

Cancer Network presents exclusive coverage of prostate cancer from the American Society of Clinical Oncology (ASCO) 2014 annual meeting. We'll bring you reports and interviews as we cover the latest research, trials, scientific advances, and controversies that are changing the way prostate cancer is managed and treated.

ASCO 2014 Prostate Cancer

Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.

The results of the CHAARTED trial, which looked at whether the addition of upfront chemotherapy to hormonal therapy improved overall survival in patients with hormone-sensitive metastatic prostate cancer, were presented at the ASCO Annual Meeting.

The investigational therapy orteronel delayed disease progression in patients with metastatic castration-resistant prostate cancer, but did not significantly improve overall survival.

A phase I trial that combined the investigational therapy cabozantinib with the already approved abiraterone acetate in metastatic castration-resistant prostate cancer patients shows that the two agents are tolerable, with the potential for improved efficacy.

An analysis of clinical trials suggests that the site of a prostate cancer patient’s metastases can predict survival following treatment with docetaxel.

Results from the phase III E3805 clinical trial show that adding docetaxel to standard hormone therapy extends survival for men with metastatic hormone-sensitive prostate cancer by 13.6 months.

Researchers have demonstrated the ability to detect AR-V7 in circulating tumor cells of prostate cancer patients with primary resistance to enzalutamide and abiraterone.


Subscribe to ASCO 2014 Prostate Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.